Figure 5.

Effect of the MR antagonist spironolactone on extracellular dopamine in the nucleus accumbens. The i.c.v. administration of spironolactone (100 ng/6 μl), did not significantly modify dopamine release, neither in basal conditions nor in response to a morphine injection (2 mg/kg, s.c.). Each point represents the mean ± SEM of dopamine collected over 20 min. The GR antagonist were administered 2–2.5 hr before the injection of morphine.